Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus atezolizumab after definitive chemoradiotherapy in unresectable esophageal squamous cell carcinoma
PACTR202201585469592Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Tiragolumab plus atezolizumab, Placebo plus atezolizumab and Double placebo (3 arms). Primary endpoints: Investigator-assessed progression-free survival and Overall survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on PACTR202201585469592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201585469592.